Cite
21MO Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC.
MLA
Shao, Z., et al. “21MO Primary Results of a China Bridging, Phase II Randomized Study of Initial Endocrine Therapy (ET) ± Ribociclib (RIB) in Pre- & Postmenopausal Chinese Women with HR+/HER2– ABC.” Annals of Oncology, vol. 33, Nov. 2022, p. S1438. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.10.030.
APA
Shao, Z., Liu, Q., Tong, Z., Li, W., Cai, L., Bai, Y., Amin, K., Deshpande, P., Bi, Y., & Xu, B. (2022). 21MO Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC. Annals of Oncology, 33, S1438. https://doi.org/10.1016/j.annonc.2022.10.030
Chicago
Shao, Z., Q. Liu, Z. Tong, W. Li, L. Cai, Y. Bai, K. Amin, P. Deshpande, Y. Bi, and B. Xu. 2022. “21MO Primary Results of a China Bridging, Phase II Randomized Study of Initial Endocrine Therapy (ET) ± Ribociclib (RIB) in Pre- & Postmenopausal Chinese Women with HR+/HER2– ABC.” Annals of Oncology 33 (November): S1438. doi:10.1016/j.annonc.2022.10.030.